![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1402589
½ºÇÁ¶óÀ̼¿ ½ÃÀå, ¿ëµµº°, ¿¬·É´ëº°, À¯Åë ä³Îº°, Áö¿ªº°Sprycel Market, By Application (Chronic myeloid leukemia, Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia), By Age Group, By Distribution Channel:, By Region |
¼¼°è ½ºÇÁ¶óÀ̼¿ ½ÃÀå ±Ô¸ð´Â 2023³â 22¾ï 2,000¸¸ ´Þ·¯·Î ÃßÁ¤ ¹× ¿¹ÃøµÇ¸ç, 2030³â¿¡´Â 26¾ï 9,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ¿¹Ãø ±â°£ µ¿¾È 2.8%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
º¸°í ¹üÀ§ | º¸°í¼ »ó¼¼ | ||
---|---|---|---|
±âÁØ ¿¬µµ | 2022³â | 2023³â ½ÃÀå ±Ô¸ð | 22¾ï 2,000¸¸ ´Þ·¯ |
½ÇÀû µ¥ÀÌÅÍ | 2018-2021³â | ¿¹Ãø ±â°£ | 2023-2030³â |
¿¹Ãø ±â°£ÀÇ CAGR | 2.80% | 2030³â ½ÃÀå ±Ô¸ð ¿¹Ãø | 26¾ï 9,000¸¸ ´Þ·¯ |
½ºÇÁ¶óÀ̼¿Àº ´Ù»çƼ´ÕÀÇ »óǰ¸íÀ¸·Î, ƯÁ¤ ¾Ï Ä¡·á¿¡ »ç¿ëµÇ´Â ¾à¹°ÀÔ´Ï´Ù. ´Ù»çƼ´ÕÀº Ƽ·Î½Å Ű³ª¾ÆÁ¦ ¾ïÁ¦Á¦(TKI)·Î ¾Ë·ÁÁø ¾à¹°±º¿¡ ¼ÓÇÕ´Ï´Ù. ´Ù»çƼ´ÕÀº ¾Ï¼¼Æ÷ÀÇ ¼ºÀå°ú ÀüÀÌ¿¡ °ü¿©ÇÏ´Â È¿¼ÒÀΠƯÁ¤ Ƽ·Î½Å Ű³ª¾ÆÁ¦ÀÇ È°¼ºÀ» ¾ïÁ¦ÇÏ´Â ¹æ½ÄÀ¸·Î ÀÛ¿ëÇÕ´Ï´Ù. ½ºÇÁ¶óÀ̼¿Àº ÁַΠƯÁ¤ À¯ÇüÀÇ ¹éÇ÷º´, ƯÈ÷ Çʶóµ¨ÇÇ¾Æ ¿°»öüÀÇ Á¸À縦 Ư¡À¸·Î ÇÏ´Â ±Þ¼º ¸²ÇÁ±¸¼º ¹éÇ÷º´(ALL)(Ph ALL)°ú ¸¸¼º °ñ¼ö¼º ¹éÇ÷º´(CML) Ä¡·á¿¡ »ç¿ëµÇ´Â Ç¥Àû Ä¡·áÁ¦ÀÔ´Ï´Ù. ½ºÇÁ¶óÀ̼¿ÀÇ ÀϹÝÀûÀÎ ºÎÀÛ¿ëÀ¸·Î´Â ÇÇ·Î, µÎÅë, ¸Þ½º²¨¿ò, ¼³»ç, ü¾× Àú·ù µîÀÌ ÀÖ½À´Ï´Ù. ÀϺΠȯÀÚ´Â Ç÷±¸ ¼ö °¨¼Ò, °£ ¼Õ»ó, ÃâÇ÷°ú °°Àº ´õ ½É°¢ÇÑ ºÎÀÛ¿ëÀÌ ³ªÅ¸³¯ ¼ö ÀÖ½À´Ï´Ù. ºÎÀÛ¿ëÀ» °ü¸®ÇÏ°í ´ëóÇϱâ À§Çؼ´Â ÀÇ·áÁøÀÇ ¸é¹ÐÇÑ ¸ð´ÏÅ͸µÀÌ Áß¿äÇϸç, CML Áø´ÜÀ» ¹ÞÀº 12°³¿ù ÀÌ»óÀÇ ¼ºÀΰú ¼Ò¾Æ ¸ðµÎ¿¡°Ô Åõ¿©µË´Ï´Ù. ¶ÇÇÑ, Çʶóµ¨ÇÇ¾Æ ¿°»öü ¾ç¼º ¶Ç´Â Ph ALL·Î ¾Ë·ÁÁø ±Þ¼º ¸²ÇÁ¸ð±¸ ¹éÇ÷º´ÀÇ Æ¯Á¤ ¾ÆÇüÀ» ¾Î°í ÀÖ´Â °°Àº ¿¬·É´ëÀÇ ¼ºÀΰú ¼Ò¾Æ¿¡°Ôµµ ó¹æµË´Ï´Ù. ¹éÇ÷º´Àº °ñ¼ö¿¡¼ ¹ß»ýÇÏ´Â ¹Ì¼º¼÷ ¹éÇ÷±¸°¡ °ü¿©ÇÏ´Â ¾Ç¼º Á¾¾çÀÔ´Ï´Ù. Á¤»óÀûÀÎ °úÁ¤¿¡¼ ÀÌ ¹éÇ÷±¸°¡ ¼º¼÷ÇÏ¸é °¨¿°°ú ½Î¿ì°í ½ÅüÀÇ ¸é¿ª ü°è¸¦ À¯ÁöÇϱâ À§ÇØ Ç÷·ù·Î µé¾î°¡°Ô µË´Ï´Ù.
Ç¥Àû ÀûÀÀÁõ Áõ°¡, È¿´É ¹× ¾ÈÀü¼º ÇÁ·ÎÆÄÀÏ, ÀûÀÀÁõ È®´ë, Çõ½ÅÀû ¹ßÀüÀº ¿¹Ãø ±â°£ µ¿¾È ¼¼°è ½ºÇÁ¶óÀ̼¿ ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÁÖ¿ä ¿äÀÎÀÔ´Ï´Ù. ½ºÇÁ¶óÀ̼¿°ú °°Àº Ç¥ÀûÄ¡·áÁ¦ °³¹ßÀ» Æ÷ÇÔÇÑ ¾Ï ¿¬±¸ ¹× Ä¡·áÀÇ ¹ßÀüÀº ÀÇ·á Á¦°øÀÚ¿Í È¯ÀÚ°¡ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¼±ÅñÇÀ» È®´ëÇß½À´Ï´Ù. ÀÌ·Î ÀÎÇØ Ä¡·á ¿ä¹ýÀÇ ÀÏȯÀ¸·Î ½ºÇÁ¶óÀ̼¿ÀÇ Ã¤ÅÃÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.
±×·¯³ª °·ÂÇÑ °æÀï, ƯÇã ¸¸·á, ±ÔÁ¦ ¹®Á¦, ºÎÀÛ¿ë, °¡°Ý Ã¥Á¤ ¹× »óȯÀº ¿¹Ãø ±â°£ µ¿¾È ¼¼°è ½ºÇÁ¶óÀ̼¿ ½ÃÀåÀÇ ¼ºÀåÀ» ÀúÇØÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
The global Sprycel market size is estimated to be valued at US$ 2.22 billion in 2023 and is projected to reach US$ 2.69 billion by 2030, growing at a CAGR of 2.8% during the forecast period.
Report Coverage | Report Details | ||
---|---|---|---|
Base Year: | 2022 | Market Size in 2023: | US$ 2.22 Bn |
Historical Data for: | 2018 to 2021 | Forecast Period: | 2023 - 2030 |
Forecast Period 2023 to 2030 CAGR: | 2.80% | 2030 Value Projection: | US$ 2.69 Bn |
Sprycel is the brand name for dasatinib, a medication used in the treatment of certain types of cancer. It belongs to a class of drugs known as tyrosine kinase inhibitors (TKIs). Dasatinib works by inhibiting the activity of specific tyrosine kinases, which are enzymes involved in the growth and spread of cancer cells. Sprycel is a targeted medication primarily employed in the treatment of certain types of leukemia, specifically acute lymphoblastic leukemia (ALL), characterized by the presence of the Philadelphia chromosome (Ph+ ALL), and chronic myeloid leukemia (CML). Common side effects of Sprycel may include fatigue, headache, nausea, diarrhea, and fluid retention. Some patients may also experience more serious side effects, such as low blood cell counts, liver problems, and bleeding. Close monitoring by healthcare providers is important to manage and address any adverse effects. It is administered to both adults and children aged 12 months and older who are diagnosed with CML. Additionally, it is prescribed for adults and children in the same age group who are afflicted with a specific subtype of acute lymphoblastic leukemia known as Philadelphia chromosome-positive or Ph+ ALL. Leukemia is a malignancy involving immature white blood cells that develop within the bone marrow. In the normal course of events, as these white blood cells mature, they enter the bloodstream to combat infections and maintain the body's immune system.
The increasing prevalence of targeted indications, their efficacy and safety profile, expanded indications, and innovative advancements are major factors expected to drive growth of the global sprycel market during the forecast period. Advancements in cancer research and treatment, including the development of targeted therapies like Sprycel, have expanded the options available to healthcare providers and patients. This has led to increased adoption of Sprycel as part of the treatment regimen.
However, strong competition, patent expiration, regulatory challenges, adverse effects, and pricing and reimbursement are expected to hamper the growth of the global Sprycel market over the forecast period.